Sudden death risk stratification in non-ischemic dilated cardiomyopathy using old and new tools: a clinical challenge

References

• Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29(2):270–276.
   PubMed Web of Science ®Google Scholar
• Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850–1858.
   PubMed Web of Science ®Google Scholar
• Goldberger JJ, Subacius H, Patel T, et al. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014;63(18):1879–1889.
   PubMed Web of Science ®Google Scholar
• Manolis AS. Preventing sudden death in idiopathic dilated cardiomyopathy: A difficult to settle issue. Rhythmos. 2017;12(1):1–6.
   Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American college of cardiology/American heart association task force on practice guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American association for thoracic surgery and society of thoracic surgeons. J Am Coll Cardiol. 2008;51(21):e1–62.
   PubMed Web of Science ®Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61(3):e6–75.
   PubMed Web of Science ®Google Scholar
• Brignole M, Auricchio A, Baron-Esquivias G, et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34(29):2281–2329.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: association for european paediatric and congenital cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the oregon sudden unexpected death study. J Am Coll Cardiol. 2006;47(6):1161–1166.
   PubMed Web of Science ®Google Scholar
• Lip GY, Heinzel FR, Gaita F, et al. European heart rhythm association/heart failure association joint consensus document on arrhythmias in heart failure, endorsed by the heart rhythm society and the Asia pacific heart rhythm society. Eur J Heart Fail. 2015;17(9):848–874.
   PubMed Web of Science ®Google Scholar
• Broch K, Murbraech K, Andreassen AK, et al. Contemporary outcome in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2015;116(6):952–959.
   PubMed Web of Science ®Google Scholar
• Arbustini E, Disertori M, Narula J. Primary prevention of sudden arrhythmic death in dilated cardiomyopathy: current guidelines and risk stratification. JACC Heart Fail. 2017;5(1):39–43.
   PubMed Web of Science ®Google Scholar
• Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT). Circulation. 2002;105(12):1453–1458.
   PubMed Web of Science ®Google Scholar
• Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomizedtrial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol. 2003;41(10):1707–1712.
   PubMed Web of Science ®Google Scholar
• Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–2158.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–2150.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237.
   PubMed Web of Science ®Google Scholar
• Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–1230.
   PubMed Web of Science ®Google Scholar
• Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the marburg cardiomyopathy study. Circulation. 2003;108(23):2883–2891.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–1549.
   PubMed Web of Science ®Google Scholar
• Jarcho JA. Resynchronizing ventricular contraction in heart failure. N Engl J Med. 2005;352(15):1594–1597.
   PubMed Web of Science ®Google Scholar
• Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. Jama. 2004;292(23):2874–2879.
   PubMed Web of Science ®Google Scholar
• McMurray JJ. The ICD in Heart Failure - Time for a Rethink? N Engl J Med. 2016;375(13):1283–1284.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367(24):2275–2283.
   PubMed Web of Science ®Google Scholar
• Golwala H, Bajaj NS, Arora G, et al. Implantable cardioverter-defibrillator for non ischemic cardiomyopathy: an updated meta-analysis. Circulation. 2017;135(2):201–203.
   PubMed Web of Science ®Google Scholar
• Japp AG, Gulati A, Cook SA, et al. Evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67(25):2996–3010.
   PubMed Web of Science ®Google Scholar
• Memon S, Ganga HV, Kluger J. Late gadolinium enhancement in patients with nonischemic dilated cardiomyopathy. Pacing Clin Electrophysiol. 2016;39(7):731–747.
   PubMed Web of Science ®Google Scholar
• Makati KJ, Fish AE, England HH, et al. Equivalent arrhythmic risk in patients recently diagnosed with dilated cardiomyopathy compared with patients diagnosed for 9 months or more. Heart Rhythm. 2006;3(4):397–403.
   PubMed Web of Science ®Google Scholar
• Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Heart Rhythm. 2014;11(7):1271–1303.
   PubMed Web of Science ®Google Scholar
• Losurdo P, Stolfo D, Merlo M, et al. Early arrhythmic events in idiopathic dilated cardiomyopathy. J Am Coll Cardiol EP. 2016;2:535–543.
   Google Scholar
• Voskoboinik A, Bloom J, Taylor A, et al. Early implantation of primary prevention implantable cardioverter defibrillators for patients with newly diagnosed severe nonischemic cardiomyopathy. Pacing Clin Electrophysiol. 2016;39(9):992–998.
   PubMed Web of Science ®Google Scholar
• Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013;61(12):1318–1368.
   PubMed Web of Science ®Google Scholar
• Mealing S, Woods B, Hawkins N, et al. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart. 2016;102(21):1742–1749.
   PubMed Web of Science ®Google Scholar
• Chen X, Shenasa M, Borggrefe M, et al. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients. Eur Heart J. 1994;15(1):76–82.
   PubMed Web of Science ®Google Scholar
• Hsia HH, Marchlinski FE. Electrophysiology studies in patients with dilated cardiomyopathies. Card Electrophysiol Rev. 2002;6(4):472–481.
   PubMedGoogle Scholar
• Becker R, Haass M, Ick D, et al. Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy. Basic Res Cardiol. 2003;98(4):259–266.
   PubMed Web of Science ®Google Scholar
• Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009;32(6):755–761.
   PubMed Web of Science ®Google Scholar
• Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2013;6(3):504–512.
   PubMed Web of Science ®Google Scholar
• Rolf S, Haverkamp W, Borggrefe M, et al. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis. Europace. 2009;11(3):289–296.
   PubMed Web of Science ®Google Scholar
• Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy. Am Coll Cardiol HF. 2017;5:28–38.
   Google Scholar
• Mueller KA, Heck C, Heinzmann D, et al. Comparison of ventricular inducibility with late gadolinium enhancement and myocardial inflammation in endomyocardial biopsy in patients with dilated cardiomyopathy. Plos One. 2016;11(12):e0167616.
   Google Scholar
• Chimura M, Onishi T, Tsukishiro Y, et al. Longitudinal strain combined with delayed-enhancement magnetic resonance improves risk stratification in patients with dilated cardiomyopathy. Heart. 2016. [Epub ahead of print]. DOI:10.1136/heartjnl-2016-309746
   PubMedGoogle Scholar
• Mikami Y, Jolly U, Heydari B, et al. Right ventricular ejection fraction is incremental to left ventricular ejection fraction for the prediction of future arrhythmic events in patients with systolic dysfunction. Circ Arrhythm Electrophysiol. 2017;10:1.
   Web of Science ®Google Scholar
• Daubert JP, Lewis RK. Smarter deployment of implantable cardioverter-defibrillators in nonischemic cardiomyopathy: feasible or mythical? J Am Coll Cardiol. 2014;63(18):1890–1891.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51(3):288–296.
   PubMed Web of Science ®Google Scholar
• Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 2012;59(23):2075–2079.
   PubMed Web of Science ®Google Scholar
• De Gonzalo-Calvo D, Quezada M, Campuzano O, et al. Familial dilated cardiomyopathy: A multidisciplinary entity, from basic screening to novel circulating biomarkers. Int J Cardiol. 2017;228:870–880.
   PubMed Web of Science ®Google Scholar
• Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, et al. Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant. 2016;35(5):625–635.
   PubMed Web of Science ®Google Scholar
• Mestroni L, Taylor MR. Genetics and genetic testing of dilated cardiomyopathy: a new perspective. Discov Med. 2013;15(80):43–49.
   PubMed Web of Science ®Google Scholar
• Van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59(5):493–500.
   PubMed Web of Science ®Google Scholar
• Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52(15):1250–1260.
   PubMed Web of Science ®Google Scholar
• Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol.  2017;106(2):127–139.
   PubMed Web of Science ®Google Scholar
• Ollila L, Nikus K, Holmstrom M, et al. Clinical disease presentation and ECG characteristics of LMNA mutation carriers. Open Heart. 2017;4(1):e000474.
   Google Scholar
• Seidelmann SB, Laur O, Hwa J, et al. Familial dilated cardiomyopathy diagnosis is commonly overlooked at the time of transplant listing. J Heart Lung Transplant. 2016;35(4):474–480.
   PubMed Web of Science ®Google Scholar
• Spezzacatene A, Sinagra G, Merlo M, et al. Arrhythmogenic phenotype in dilated cardiomyopathy: natural history and predictors of life-threatening arrhythmias. J Am Heart Assoc. 2015;4(10):e002149.
   Google Scholar
• Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemotherapy. 2017;62(3):159–168.
   PubMed Web of Science ®Google Scholar
• Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Med Oncol. 2016;33(8):84.
   PubMed Web of Science ®Google Scholar
• Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-2648, 2648a-2648d.
   Web of Science ®Google Scholar
• Lenarczyk R, Potpara TS, Haugaa KH, et al. The use of wearable cardioverter-defibrillators in Europe: results of the European Heart Rhythm Association survey. Europace. 2016;18(1):146–150.
   PubMed Web of Science ®Google Scholar
• Raimondi F, Iserin F, Raisky O, et al. Myocardial inflammation on cardiovascular magnetic resonance predicts left ventricular function recovery in children with recent dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2015;16(7):756–762.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(19):1448–1458.
   PubMed Web of Science ®Google Scholar
• Gao G, Brahmanandam V, Raicu M, et al. Enhanced risk profiling of implanted defibrillator shocks with circulating SCN5A mRNA splicing variants: a pilot trial. J Am Coll Cardiol. 2014;63(21):2261–2269.
   PubMed Web of Science ®Google Scholar
• Schulte-Frohlinde V, Ashkenazy Y, Goldberger AL, et al. Complex patterns of abnormal heartbeats. Phys Rev E Stat Nonlin Soft Matter Phys. 2002;66(3 Pt 1):031901.
   Google Scholar